DOCSLIB.ORG

IDSA/ATS Consensus Guidelines on The

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IDSA/ATS Consensus Guidelines on The SUPPLEMENT ARTICLE Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults Lionel A. Mandell,1,a Richard G. Wunderink,2,a Antonio Anzueto,3,4 John G. Bartlett,7 G. Douglas Campbell,8 Nathan C. Dean,9,10 Scott F. Dowell,11 Thomas M. File, Jr.12,13 Daniel M. Musher,5,6 Michael S. Niederman,14,15 Antonio Torres,16 and Cynthia G. Whitney11 1McMaster University Medical School, Hamilton, Ontario, Canada; 2Northwestern University Feinberg School of Medicine, Chicago, Illinois; 3University of Texas Health Science Center and 4South Texas Veterans Health Care System, San Antonio, and 5Michael E. DeBakey Veterans Affairs Medical Center and 6Baylor College of Medicine, Houston, Texas; 7Johns Hopkins University School of Medicine, Baltimore, Maryland; 8Division of Pulmonary, Critical Care, and Sleep Medicine, University of Mississippi School of Medicine, Jackson; 9Division of Pulmonary and Critical Care Medicine, LDS Hospital, and 10University of Utah, Salt Lake City, Utah; 11Centers for Disease Control and Prevention, Atlanta, Georgia; 12Northeastern Ohio Universities College of Medicine, Rootstown, and 13Summa Health System, Akron, Ohio; 14State University of New York at Stony Brook, Stony Brook, and 15Department of Medicine, Winthrop University Hospital, Mineola, New York; and 16Cap de Servei de Pneumologia i Alle`rgia Respirato`ria, Institut Clı´nic del To`rax, Hospital Clı´nic de Barcelona, Facultat de Medicina, Universitat de Barcelona, Institut d’Investigacions Biome`diques August Pi i Sunyer, CIBER CB06/06/0028, Barcelona, Spain. EXECUTIVE SUMMARY priate starting point for consultation by specialists. Substantial overlap exists among the patients whom Improving the care of adult patients with community- these guidelines address and those discussed in the re- acquired pneumonia (CAP) has been the focus of many cently published guidelines for health care–associated different organizations, and several have developed pneumonia (HCAP). Pneumonia in nonambulatory guidelines for management of CAP. Two of the most residents of nursing homes and other long-term care widely referenced are those of the Infectious Diseases facilities epidemiologically mirrors hospital-acquired Society of America (IDSA) and the American Thoracic pneumonia and should be treated according to the Society (ATS). In response to confusion regarding dif- HCAP guidelines. However, certain other patients ferences between their respective guidelines, the IDSA whose conditions are included in the designation of and the ATS convened a joint committee to develop a HCAP are better served by management in accordance unified CAP guideline document. with CAP guidelines with concern for specific The guidelines are intended primarily for use by pathogens. emergency medicine physicians, hospitalists, and pri- mary care practitioners; however, the extensive litera- Implementation of Guideline Recommendations ture evaluation suggests that they are also an appro- 1. Locally adapted guidelines should be imple- Reprints or correspondence: Dr. Lionel A. Mandell, Div. of Infectious Diseases, mented to improve process of care variables and McMaster University/Henderson Hospital, 5th Fl., Wing 40, Rm. 503, 711 relevant clinical outcomes. (Strong recommen- Concession St., Hamilton, Ontario L8V 1C3, Canada ([email protected]). This official statement of the Infectious Diseases Society of America (IDSA) dation; level I evidence.) and the American Thoracic Society (ATS) was approved by the IDSA Board of Directors on 5 November 2006 and the ATS Board of Directors on 29 September 2006. It is important to realize that guidelines cannot always account for individual a Committee cochairs. variation among patients. They are not intended to supplant physician judgment Clinical Infectious Diseases 2007;44:S27–72 with respect to particular patients or special clinical situations. The IDSA considers ᮊ 2007 by the Infectious Diseases Society of America. All rights reserved. adherence to these guidelines to be voluntary, with the ultimate determination 1058-4838/2007/4405S2-0001$15.00 regarding their application to be made by the physician in the light of each patient’s DOI: 10.1086/511159 individual circumstances. IDSA/ATS Guidelines for CAP in Adults • CID 2007:44 (Suppl 2) • S27 Enthusiasm for developing these guidelines derives, in large take oral medication and the availability of outpatient support part, from evidence that previous CAP guidelines have led to resources. improvement in clinically relevant outcomes. Consistently ben- ICU admission decision. eficial effects in clinically relevant parameters (listed in table 3) 7. Direct admission to an ICU is required for patients with followed the introduction of a comprehensive protocol (in- septic shock requiring vasopressors or with acute respi- cluding a combination of components from table 2) that in- ratory failure requiring intubation and mechanical ven- creased compliance with published guidelines. The first rec- tilation. (Strong recommendation; level II evidence.) ommendation, therefore, is that CAP management guidelines 8. Direct admission to an ICU or high-level monitoring unit be locally adapted and implemented. is recommended for patients with 3 of the minor criteria Documented benefits. for severe CAP listed in table 4. (Moderate recommen- 2. CAP guidelines should address a comprehensive set of dation; level II evidence.) elements in the process of care rather than a single element In some studies, a significant percentage of patients with in isolation. (Strong recommendation; level III evidence.) CAP are transferred to the ICU in the first 24–48 h after hos- 3. Development of local CAP guidelines should be directed pitalization. Mortality and morbidity among these patients ap- toward improvement in specific and clinically relevant pears to be greater than those among patients admitted directly outcomes. (Moderate recommendation; level III to the ICU. Conversely, ICU resources are often overstretched evidence.) in many institutions, and the admission of patients with CAP who would not directly benefit from ICU care is also problem- atic. Unfortunately, none of the published criteria for severe Site-of-Care Decisions CAP adequately distinguishes these patients from those for Almost all of the major decisions regarding management of whom ICU admission is necessary. In the present set of guide- CAP, including diagnostic and treatment issues, revolve lines, a new set of criteria has been developed on the basis of around the initial assessment of severity. Site-of-care decisions data on individual risks, although the previous ATS criteria (e.g., hospital vs. outpatient, intensive care unit [ICU] vs. format is retained. In addition to the 2 major criteria (need general ward) are important areas for improvement in CAP for mechanical ventilation and septic shock), an expanded set management. of minor criteria (respiratory rate, 130 breaths/min; arterial Hospital admission decision. oxygen pressure/fraction of inspired oxygen (PaO2/FiO2) ratio, 4. Severity-of-illness scores, such as the CURB-65 criteria !250; multilobar infiltrates; confusion; blood urea nitrogen (confusion, uremia, respiratory rate, low blood pressure, level, 120 mg/dL; leukopenia resulting from infection; throm- age 65 years or greater), or prognostic models, such as bocytopenia; hypothermia; or hypotension requiring aggressive the Pneumonia Severity Index (PSI), can be used to iden- fluid resuscitation) is proposed (table 4). The presence of at tify patients with CAP who may be candidates for out- least 3 of these criteria suggests the need for ICU care but will patient treatment. (Strong recommendation; level I require prospective validation. evidence.) 5. Objective criteria or scores should always be supple- Diagnostic Testing mented with physician determination of subjective fac- tors, including the ability to safely and reliably take oral 9. In addition to a constellation of suggestive clinical fea- medication and the availability of outpatient support re- tures, a demonstrable infiltrate by chest radiograph or sources. (Strong recommendation; level II evidence.) other imaging technique, with or without supporting mi- у 6. For patients with CURB-65 scores 2, more-intensive crobiological data, is required for the diagnosis of pneu- treatment—that is, hospitalization or, where appropriate monia. (Moderate recommendation; level III evidence.) and available, intensive in-home health care services—is Recommended diagnostic tests for etiology. usually warranted. (Moderate recommendation; level III 10. Patients with CAP should be investigated for specific evidence.) pathogens that would significantly alter standard (em- Physicians often admit patients to the hospital who could pirical) management decisions, when the presence of be well managed as outpatients and who would generally prefer such pathogens is suspected on the basis of clinical and to be treated as outpatients. Objective scores, such as the CURB- epidemiologic clues. (Strong recommendation; level II 65 score or the PSI, can assist in identifying patients who may evidence.) be appropriate for outpatient care, but the use of such scores Recommendations for diagnostic testing remain controver- must be tempered by the physician’s determination of addi- sial. The overall low yield and infrequent positive impact on tional critical factors, including the ability to safely and reliably clinical care argue against the routine use of common
Load more

Recommended publications
  • Etiology of Pulmonary Abscess
    University of Nebraska Medical Center DigitalCommons@UNMC MD Theses Special Collections 5-1-1933 Etiology of pulmonary abscess Lucien Sears University of Nebraska Medical Center This manuscript is historical in nature and may not reflect current medical research and practice. Search PubMed for current research. Follow this and additional works at: https://digitalcommons.unmc.edu/mdtheses Recommended Citation Sears, Lucien, "Etiology of pulmonary abscess" (1933). MD Theses. 291. https://digitalcommons.unmc.edu/mdtheses/291 This Thesis is brought to you for free and open access by the Special Collections at DigitalCommons@UNMC. It has been accepted for inclusion in MD Theses by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. THE ETIOLOG~ OF PUL~ONARY ABSCESS By Lucien Sears University of Nebraska Medical College • Senior Thesis 1933 "?REFACE The purpose of this paper is to pre- sent so far as possible a modern and ra- tional explanation of the etiology of pul- monary abscess. No attempt has been made, in writing this paper, to include the symptomatology, pathology, diagnosis or therapy of pulmon­ ary abscess. The references were chosen with the idea that they are useful references, that is to say references which I have found use- ful, although for the most part quite recent, they will be found to contain a number of older articles. INTRODUCTION. The term lung abscess has come to be rather loose­ ly applied to a variety of conditions. Strictly speak­ ing it consists of a focus of suppuration within the parenchyma of the lung; but in current literature has come to include suppuration within the bronchial tree and even between apposing pleural surfaces.
    [Show full text]
  • Guide to Infection Control in the Healthcare Setting
    GUIDE TO INFECTION CONTROL IN THE HEALTHCARE SETTING Pneumococcus Author Roman Pallares, MD Imma Grau, MD Chapter Editor Ziad A. Memish, MD, FRCPC, FACP Topic Outline Key Issues Known Facts Controversial Issues Suggested Practice Suggested Practice in Under-Resourced Settings Summary References Chapter last updated: April 2018 KEY ISSUE • Streptococcus pneumoniae (Pneumococcus) remains a major pathogen worldwide, mainly in young children (<5 years), adults with immunosuppressive or chronic diseases as well as smokers and alcohol abusers, and older adults (≥65 years). Pneumococcal disease is more common in developing countries and occurs more often during winter. In recent years, important changes in the epidemiology of pneumococcal infections have been observed: 1. The emergence and spread of antibiotic-resistant pneumococci which make invasive pneumococcal infections (e.g., meningitis) difficult to treat. 2. The increased prevalence of pneumococcal disease in the elderly and in patients with chronic and serious underlying conditions (e.g., HIV, malignancies). 3. The increasing recognition of pneumococcal infections in patients admitted to healthcare institutions and nursing homes, childcare centers, and other closed institutions (e.g., jails, military camps). Several of these infections appeared as outbreaks due to antibiotic- resistant pneumococci. 4. In the years 2000s, there was a reduction in the incidence of pneumococcal infections after the introduction of pneumococcal conjugate vaccines (7-valent “PCV7”, 10-valent “PCV10”, and 13- valent “PCV13”) in children. • Most pneumococcal infections are considered community-acquired infections, and little attention has been paid to nosocomial and healthcare-associated pneumococcal infections. In addition, infection control measures for preventing pneumococcal infections in hospital and healthcare settings and nursing home facilities have not been widely considered in the literature.
    [Show full text]
  • Cefalexin in the WHO Essential Medicines List for Children Reject
    Reviewer No. 1: checklist for application of: Cefalexin In the WHO Essential Medicines List for Children (1) Have all important studies that you are aware of been included? Yes No 9 (2) Is there adequate evidence of efficacy for the proposed use? Yes 9 No (3) Is there evidence of efficacy in diverse settings and/or populations? Yes 9 No (4) Are there adverse effects of concern? Yes 9 No (5) Are there special requirements or training needed for safe/effective use? Yes No 9 (6) Is this product needed to meet the majority health needs of the population? Yes No 9 (7) Is the proposed dosage form registered by a stringent regulatory authority? Yes 9 No (8) What action do you propose for the Committee to take? Reject the application for inclusion of the following presentations of cefalexin: • Tablets/ capsules 250mg • Oral suspensions 125mg/5ml and 125mg/ml (9) Additional comment, if any. In order to identify any additional literature, the following broad and sensitive search was conducted using the PubMed Clinical Query application: (cephalexin OR cefalexin AND - 1 - pediatr*) AND ((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR clinical trial[Publication Type] OR random*[Title/Abstract] OR random allocation[MeSH Terms] OR therapeutic use[MeSH Subheading]) Only one small additional study was identified, which looked at the provision of prophylactic antibiotics in patients presenting to an urban children's hospital with trauma to the distal fingertip, requiring repair.1 In a prospective randomised control trial, 146 patients were enrolled, of which 69 were randomised to the no-antibiotic group, and 66 were randomised to the antibiotic (cefalexin) group.
    [Show full text]
  • SIGN158 British Guideline on the Management of Asthma
    SIGN158 British guideline on the management of asthma A national clinical guideline First published 2003 Revised edition published July 2019 Key to evidence statements and recommendations Levels of evidence 1++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1+ Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1– Meta-analyses, systematic reviews, or RCTs with a high risk of bias 2++ High-quality systematic reviews of case-control or cohort studies High-quality case-control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal 2+ Well-conducted case-control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal 2– Case-control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal 3 Non-analytic studies, eg case reports, case series 4 Expert opinion Grades of recommendation Note: The grade of recommendation relates to the strength of the supporting evidence on which the evidence is based. It does not reflect the clinical importance of the recommendation. A At least one meta-analysis, systematic review, or RCT rated as 1++, and directly applicable to the target population; or A body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results B A body of evidence including studies rated
    [Show full text]
  • Contemporary Clinical Trials Communications 16 (2019) 100488
    Contemporary Clinical Trials Communications 16 (2019) 100488 Contents lists available at ScienceDirect Contemporary Clinical Trials Communications journal homepage: http://www.elsevier.com/locate/conctc Opinion paper Creating an academic research organization to efficiently design, conduct, coordinate, and analyze clinical trials: The Center for Clinical Trials & Data Coordination Kaleab Z. Abebe *, Andrew D. Althouse, Diane Comer, Kyle Holleran, Glory Koerbel, Jason Kojtek, Joseph Weiss, Susan Spillane Center for Clinical Trials & Data Coordination, Division of General Internal Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA ARTICLE INFO ABSTRACT Keywords: When properly executed, the randomized controlled trial is one of the best vehicles for assessing the effectiveness Data coordinating center of one or more interventions. However, numerous challenges may emerge in the areas of study startup, Clinical trial management recruitment, data quality, cost, and reporting of results. The use of well-run coordinating centers could help prevent these issues, but very little exists in the literature describing their creation or the guiding principles behind their inception. The Center for Clinical Trials & Data Coordination (CCDC) was established in 2015 through institutional funds with the intent of 1) providing relevant expertise in clinical trial design, conduct, coordination, and analysis; 2) advancing the careers of clinical investigators and CCDC-affiliated faculty; and 3) obtaining large data coordi­ nating center (DCC) grants. We describe the organizational structure of the CCDC as well as the homegrown clinical trial management system integrating nine crucial elements: electronic data capture, eligibility and randomization, drug and external data tracking, safety reporting, outcome adjudication, data and safety moni­ toring, statistical analysis and reporting, data sharing, and regulatory compliance.
    [Show full text]
  • Allergic Bronchopulmonary Aspergillosis Masquerading As Recurrent Bacterial Pneumonia
    Medical Mycology Case Reports 12 (2016) 11–13 Contents lists available at ScienceDirect Medical Mycology Case Reports journal homepage: www.elsevier.com/locate/mmcr Allergic Bronchopulmonary Aspergillosis masquerading as recurrent bacterial pneumonia Vu Le Thuong, Lam Nguyen Ho n, Ngoc Tran Van University of Medicine and Pharmacy – Ho Chi Minh city, 217 Hong Bang, Ward 11st, Dist 5, Ho Chi Minh city 70000, Vietnam article info abstract Article history: Allergic Bronchopulmonary Aspergillosis (ABPA) can be diagnosed in an asthmatic with suitable radi- Received 15 May 2016 ologic and immunological features. However ABPA is likely to be misdiagnosed with bacterial pneu- Accepted 26 June 2016 monia. Here we report a case of ABPA masquerading as recurrent bacterial pneumonia. Treatment with Available online 27 June 2016 high-dose inhaled corticosteroids was effective. To our best knowledge, this is the first reported case of Keywords: ABPA in Vietnam. Allergic bronchopulmonary aspergillosis & 2016 International Society for Human and Animal Mycology. International Society for Human and Asthma Animal Mycology Published by Elsevier B.V. All rights reserved. Inhaled corticosteroids Pneumonia Pulmonary tuberculosis 1. Introduction À120), he complained of cough and his chest X ray (CXR) showed right perihilar airspace opacities (Fig. 1A). He was diagnosed and Allergic Bronchopulmonary Aspergillosis (ABPA) is the hy- treated as a bacterial pneumonia. His cough improved and his CXR persensitive status of airway to Aspergillus which colonizes the (on day À30) came back almost normal three months later bronchial mucosa, occurring mainly in patients with asthma or (Fig. 1B). cystic fibrosis. The diagnostic criteria for ABPA articulated by Ro- Subsequently, he had a 10- day history of coughing up white- senberg, and later revised by Greenberger, has been widely used cloudy and viscous sputum before admission.
    [Show full text]
  • The Antibacterial Activity of Cefpodoxime and the Novel Β
    Session-198 b SATURDAY-279 The Antibacterial Activity of Cefpodoxime and the Novel -lactamase Inhibitor ETX1317 Against Recent Clinical Isolates of b-lactamase-producing Enterobacteriaceae Entasis Therapeutics S. McLeod1, M. Hackel2, R. Badal2, A. Shapiro1, J. Mueller1, R. Tommasi1, and A. Miller1 1-781-810-0120 1Entasis Therapeutics, Waltham, MA and 2IHMA, International Health Management Associates, Schaumburg, IL USA www.entasistx.com Abstract In vitro activity of ETX1317 vs. comparator BLIs Cumulative activity vs. 911 ESBL-enriched Enterobacteriaceae from 2013-2015 Activity vs. 35 sequenced KPC+ and/or MBL+ Enterobacteriaceae MIC (mg/L) Background β-lactamase inhibition (IC50, µM) Strain ID Species encoded bla genes IPM CAZ-AVI CPD-ETX1317 ETX1317 ETX1317 is a novel, diazabicyclooctenone inhibitor of serine β-lactamases that Number (cumulative %) of isolates inhibited at MIC (mg/L) Class A Class C Class D Drug %S* ARC3528*¥ E. cloacae AmpC [∆308-313(SKVALA)] 0.25 32 0.125 4 restores β-lactam activity against multidrug-resistant Enterobacteriaceae. ETX0282, < 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 > 32 ARC4165*¥ C. freundii CMY-2; AmpC [N366Y]; TEM-1; SHV-5 2 32 ≤0.03 4 the oral prodrug of ETX1317, is currently under investigation in combination with BLI CTX-M-15 SHV-5 KPC-2 TEM-1 AmpC* P99 OXA-24/40 OXA-48 0 5 6 14 19 34 20 27 17 18 18 733 3 CPD 10.8 ARC6479* K. oxytoca NDM-1 16 >32 32 32 cefpodoxime proxetil (CPDP), which is hydrolyzed in vivo to release cefpodoxime 0% 0.5% 1% 3% 5% 9% 11% 14% 16% 18% 20% 100% (CPD).
    [Show full text]
  • A Professional Development Framework for Paediatric Respiratory Nursing
    A professional development framework for paediatric respiratory nursing ISSN 2040-2023: British Thoracic Society Reports Vol 12, Issue 2, May 2021 1 ACKNOWLEDGEMENTS: We are grateful to colleagues at the National Paediatric Respiratory and Allergy Nurses Group (NPRANG) for their support with the development of this document. In particular: Ann McMurray Asthma Nurse Specialist, Royal Hospital for Children and Young People, Edinburgh. NPRANG Chair Bethan Almeida Clinical Nurse Specialist for Paediatric Asthma and Allergy, Imperial College Healthcare NHS Trust Tricia McGinnity Paediatric Cystic Fibrosis Nurse Specialist, Southampton Children's Hospital Emma Bushell Paediatric Respiratory Nurse Specialist – Asthma, Frimley Health NHS Foundation Trust This document has been adapted from the following publication: British Thoracic Society, A professional development framework for respiratory nursing (1). The authors of this original document are: Samantha Prigmore, Co-chair Consultant respiratory nurse, St Georges University Hospitals NHS Foundation Trust Helen Morris, Co-chair ILD nurse specialist, Wythenshawe Hospital Alison Armstrong Nurse consultant (assisted ventilation), Royal Victoria Infirmary Susan Hope Respiratory nurse specialist, Royal Stoke University Hospital Karen Heslop-Marshall Nurse consultant, Royal Victoria Infirmary Jacqui Pollington Respiratory nurse consultant, Rotherham NHS Foundation Trust CONTENTS: Introduction Method of production How to use this document Competency table (Band 5, 6, 7 and 8) Supporting evidence Acknowledgements Declarations of Interest References Content from this document may be reproduced with permission from BTS as long as you conform to the following conditions: • The text must not be altered in any way. • The correct acknowledgement must be included. 2 Introduction Paediatric respiratory nurses are an important component of the multi-professional team for a wide variety of respiratory conditions, providing holistic care for patients in a variety of settings.
    [Show full text]
  • INTUITION .THE PHILOSOPHY of HENRI BERGSON By
    THE RHYTHM OF PHILOSOPHY: INTUITION ·ANI? PHILOSO~IDC METHOD IN .THE PHILOSOPHY OF HENRI BERGSON By CAROLE TABOR FlSHER Bachelor Of Arts Taylor University Upland, Indiana .. 1983 Submitted ~o the Faculty of the Graduate College of the · Oklahoma State University in partial fulfi11ment of the requirements for . the Degree of . Master of Arts May, 1990 Oklahoma State. Univ. Library THE RHY1HM OF PlllLOSOPHY: INTUITION ' AND PfnLoSOPlllC METHOD IN .THE PHILOSOPHY OF HENRI BERGSON Thesis Approved: vt4;;. e ·~lu .. ·~ests AdVIsor /l4.t--OZ. ·~ ,£__ '', 13~6350' ii · ,. PREFACE The writing of this thesis has bee~ a tiring, enjoyable, :Qustrating and challenging experience. M.,Bergson has introduced me to ·a whole new way of doing . philosophy which has put vitality into the process. I have caught a Bergson bug. His vision of a collaboration of philosophers using his intuitional m~thod to correct, each others' work and patiently compile a body of philosophic know: ledge is inspiring. I hope I have done him justice in my description of that vision. If I have succeeded and that vision catches your imagination I hope you Will make the effort to apply it. Please let me know of your effort, your successes and your failures. With the current challenges to rationalist epistemology, I believe the time has come to give Bergson's method a try. My discovery of Bergson is. the culmination of a development of my thought, one that started long before I began my work at Oklahoma State. However, there are some people there who deserv~. special thanks for awakening me from my ' "''' analytic slumber.
    [Show full text]
  • Duration, Temporality and Self
    Duration, Temporality and Self: Prospects for the Future of Bergsonism by Elena Fell A thesis submitted in partial fulfilment for the requirements for the degree of Doctor of Philosophy in Philosophy at the University of Central Lancashire 2007 2 Student Declaration Concurrent registration for two or more academic awards I declare that white registered as a candidate for the research degree, I have not been a registered candidate or enrolled student for another award of the University or other academic or professional institution. Material submitted for another award I declare that no material contained in the thesis has been used in any other submission for an academic award and is solely my own work Signature of Candidate Type of Award Doctor of Philosophy Department Centre for Professional Ethics Abstract In philosophy time is one of the most difficult subjects because, notoriously, it eludes rationalization. However, Bergson succeeds in presenting time effectively as reality that exists in its own right. Time in Bergson is almost accessible, almost palpable in a discourse which overcomes certain difficulties of language and traditional thought. Bergson equates time with duration, a genuine temporal succession of phenomena defined by their position in that succession, and asserts that time is a quality belonging to the nature of all things rather than a relation between supposedly static elements. But Rergson's theory of duration is not organised, nor is it complete - fragments of it are embedded in discussions of various aspects of psychology, evolution, matter, and movement. My first task is therefore to extract the theory of duration from Bergson's major texts in Chapters 2-4.
    [Show full text]
  • Allergic Bronchopulmonary Aspergillosis and Severe Asthma with Fungal Sensitisation
    Allergic Bronchopulmonary Aspergillosis and Severe Asthma with Fungal Sensitisation Dr Rohit Bazaz National Aspergillosis Centre, UK Manchester University NHS Foundation Trust/University of Manchester ~ ABPA -a41'1 Severe asthma wl'th funga I Siens itisat i on Subacute IA Chronic pulmonary aspergillosjs Simp 1Ie a:spe rgmoma As r§i · bronchitis I ram une dysfu net Ion Lun· damage Immu11e hypce ractivitv Figure 1 In t@rarctfo n of Aspergillus Vliith host. ABP A, aHerg tc broncho pu~ mo na my as µe rgi ~fos lis; IA, i nvas we as ?@rgiH os 5. MANCHl·.'>I ER J:-\2 I Kosmidis, Denning . Thorax 2015;70:270–277. doi:10.1136/thoraxjnl-2014-206291 Allergic Fungal Airway Disease Phenotypes I[ Asthma AAFS SAFS ABPA-S AAFS-asthma associated with fu ngaIsensitization SAFS-severe asthma with funga l sensitization ABPA-S-seropositive a llergic bronchopulmonary aspergi ll osis AB PA-CB-all ergic bronchopulmonary aspergi ll osis with central bronchiectasis Agarwal R, CurrAlfergy Asthma Rep 2011;11:403 Woolnough K et a l, Curr Opin Pulm Med 2015;21:39 9 Stanford Lucile Packard ~ Children's. Health Children's. Hospital CJ Scanford l MEDICINE Stanford MANCHl·.'>I ER J:-\2 I Aspergi 11 us Sensitisation • Skin testing/specific lgE • Surface hydroph,obins - RodA • 30% of patients with asthma • 13% p.atients with COPD • 65% patients with CF MANCHl·.'>I ER J:-\2 I Alternar1a• ABPA •· .ABPA is an exagg·erated response ofthe imm1une system1 to AspergUlus • Com1pUcatio n of asthm1a and cystic f ibrosis (rarell·y TH2 driven COPD o r no identif ied p1 rior resp1 iratory d isease) • ABPA as a comp1 Ucation of asth ma affects around 2.5% of adullts.
    [Show full text]
  • Differentiation of Lung Cancer, Empyema, and Abscess Through the Investigation of a Dry Cough
    Open Access Case Report DOI: 10.7759/cureus.896 Differentiation of Lung Cancer, Empyema, and Abscess Through the Investigation of a Dry Cough Brittany Urso 1 , Scott Michaels 1, 2 1. College of Medicine, University of Central Florida 2. FM Medical, Inc. Corresponding author: Brittany Urso, [email protected] Abstract An acute dry cough results commonly from bronchitis or pneumonia. When a patient presents with signs of infection, respiratory crackles, and a positive chest radiograph, the diagnosis of pneumonia is more common. Antibiotic failure in a patient being treated for community-acquired pneumonia requires further investigation through chest computed tomography. If a lung mass is found on chest computed tomography, lung empyema, abscess, and cancer need to be included on the differential and managed aggressively. This report describes a 55-year-old Caucasian male, with a history of obesity, recovered alcoholism, hypercholesterolemia, and hypertension, presenting with an acute dry cough in the primary care setting. The patient developed signs of infection and was found to have a lung mass on chest computed tomography. Treatment with piperacillin-tazobactam and chest tube placement did not resolve the mass, so treatment with thoracotomy and lobectomy was required. It was determined through surgical investigation that the patient, despite having no risk factors, developed a lung abscess. Lung abscesses rarely form in healthy middle-aged individuals making it an unlikely cause of the patient's presenting symptom, dry cough. The patient cleared his infection with proper management and only suffered minor complications of mild pneumoperitoneum and pneumothorax during his hospitalization. Categories: Cardiac/Thoracic/Vascular Surgery, Infectious Disease, Pulmonology Keywords: lung abscess, empyema, lung infection, pneumonia, thoracotomy, lobectomy, pulmonology, respiratory infections Introduction Determining the etiology of an acute dry cough can be an easy diagnosis such as bronchitis or pneumonia; however, it can also develop from other etiologies.
    [Show full text]